These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 33854297)
1. Evaluating the Safety, Efficacy and Patient Acceptability of Intravitreal Fluocinolone Acetonide (0.2mcg/Day) Implant in the Treatment of Non-Infectious Uveitis Affecting the Posterior Segment. Steeples LR; Pockar S; Jones NP; Leal I Clin Ophthalmol; 2021; 15():1433-1442. PubMed ID: 33854297 [TBL] [Abstract][Full Text] [Related]
17. Injectable Fluocinolone Acetonide Long-Acting Implant for Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Two-Year Results. Jaffe GJ; Lin P; Keenan RT; Ashton P; Skalak C; Stinnett SS Ophthalmology; 2016 Sep; 123(9):1940-8. PubMed ID: 27421623 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of the Fluocinolone Acetonide (Yutiq) Intravitreal Implant as Monotherapy for Uveitis. Mahmud H; Ahmad TR; Gonzales JA; Stewart JM Ocul Immunol Inflamm; 2023 Oct; 31(8):1603-1607. PubMed ID: 35793136 [TBL] [Abstract][Full Text] [Related]
19. A comparison between the fluocinolone acetonide (Retisert) and dexamethasone (Ozurdex) intravitreal implants in uveitis. Arcinue CA; Cerón OM; Foster CS J Ocul Pharmacol Ther; 2013 Jun; 29(5):501-7. PubMed ID: 23297752 [TBL] [Abstract][Full Text] [Related]
20. In-situ forming biodegradable implants for sustained Fluocinolone acetonide release to the posterior eye: In-vitro and in-vivo investigations in rabbits. Karimi M; Abrishami M; Farzadnia M; Kamali H; Malaekeh-Nikouei B Int J Pharm; 2024 Apr; 654():123973. PubMed ID: 38458402 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]